M B Tharu1, A D Harries2, S Goel3, S Srivastava4, A M V Kumar5, M Adhikari1, B Shrestha6, B Maharjan6, H Khadka1. 1. International Nepal Fellowship, Pokhara, Nepal. 2. International Union Against Tuberculosis and Lung Disease (The Union), Paris, France ; London School of Hygiene & Tropical Medicine, London, UK. 3. School of Public Health, Post Graduate Institute of Medical Education & Research, Chandigarh, India. 4. Public Health Foundation of India, New Delhi, India. 5. The Union, South-East Asia Regional Office, New Delhi, India. 6. Nepal Anti Tuberculosis Association, GENETUP Central Reference Laboratory, Kathmandu, Nepal.
Abstract
SETTING: Multidrug-resistant tuberculosis (MDR-TB, defined as resistance to isoniazid and rifampicin) is poorly detected in Nepal; one reason may be poor functioning of culture and drug susceptibility testing (CDST) services for retreatment tuberculosis (TB) patients. OBJECTIVES: To determine, among retreatment TB patients in mid-west Nepal, 1) the number of patients registered for treatment between July 2011 and July 2012; 2) the number submitting sputum specimens for CDST to the Central Reference Laboratory (CRL), Kathmandu, along with the results; and 3) the length of time for submission and receipt of specimens. DESIGN: Retrospective cohort study involving the review of treatment and laboratory registers from the Nepalgunj TB Referral Centre and the CRL. RESULTS: Of 431 retreatment patients, 66 (15%) submitted sputum samples, of which 63 reached the CRL. Of these, 39 (62%) were culture-positive; 13 (33%) patients had MDR-TB. The CDST results of 19 patients were received back at the TB Referral Centre. The median turnaround time from sending specimens to receipt of results at the TB Referral Centre was 119 days. CONCLUSION: Less than 10% of retreatment TB patients in mid-West Nepal had CDST results recorded, leading to the underdiagnosis of MDR-TB in the region. Urgent solutions are needed to rectify this problem.
SETTING: Multidrug-resistant tuberculosis (MDR-TB, defined as resistance to isoniazid and rifampicin) is poorly detected in Nepal; one reason may be poor functioning of culture and drug susceptibility testing (CDST) services for retreatment tuberculosis (TB) patients. OBJECTIVES: To determine, among retreatment TB patients in mid-west Nepal, 1) the number of patients registered for treatment between July 2011 and July 2012; 2) the number submitting sputum specimens for CDST to the Central Reference Laboratory (CRL), Kathmandu, along with the results; and 3) the length of time for submission and receipt of specimens. DESIGN: Retrospective cohort study involving the review of treatment and laboratory registers from the Nepalgunj TB Referral Centre and the CRL. RESULTS: Of 431 retreatment patients, 66 (15%) submitted sputum samples, of which 63 reached the CRL. Of these, 39 (62%) were culture-positive; 13 (33%) patients had MDR-TB. The CDST results of 19 patients were received back at the TB Referral Centre. The median turnaround time from sending specimens to receipt of results at the TB Referral Centre was 119 days. CONCLUSION: Less than 10% of retreatment TB patients in mid-West Nepal had CDST results recorded, leading to the underdiagnosis of MDR-TB in the region. Urgent solutions are needed to rectify this problem.
Entities:
Keywords:
Nepal; central reference laboratory; culture and drug susceptibility testing; multidrug-resistant tuberculosis; operational research; retreatment tuberculosis
Authors: A D Harries; J Michongwe; T E Nyirenda; J R Kemp; S B Squire; A R Ramsay; P Godfrey-Faussett; F M Salaniponi Journal: Int J Tuberc Lung Dis Date: 2004-02 Impact factor: 2.373
Authors: M Edginton; D Enarson; R Zachariah; T Reid; S Satyanarayana; K Bissell; S G Hinderaker; T Harries Journal: Public Health Action Date: 2012-03-21
Authors: A M Kilale; B J Ngowi; G S Mfinanga; S Egwaga; B Doulla; A M V Kumar; M Khogali; J van Griensven; A D Harries; R Zachariah; S G Hinderaker Journal: Public Health Action Date: 2013-06-21
Authors: A Trébucq; D A Enarson; C Y Chiang; A Van Deun; A D Harries; F Boillot; A Detjen; P I Fujiwara; S M Graham; I Monedero; I D Rusen; H L Rieder Journal: Int J Tuberc Lung Dis Date: 2011-10-13 Impact factor: 2.373
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev Journal: Bull World Health Organ Date: 1969 Impact factor: 9.408
Authors: Anna Vassall; Sanne van Kampen; Hojoon Sohn; Joy S Michael; K R John; Saskia den Boon; J Lucian Davis; Andrew Whitelaw; Mark P Nicol; Maria Tarcela Gler; Anar Khaliqov; Carlos Zamudio; Mark D Perkins; Catharina C Boehme; Frank Cobelens Journal: PLoS Med Date: 2011-11-08 Impact factor: 11.069
Authors: Sarabjit S Chadha; B N Sharath; Kishore Reddy; Jyothi Jaju; P H Vishnu; Sreenivas Rao; Malik Parmar; Srinath Satyanarayana; Kuldeep Singh Sachdeva; Nevin Wilson; Anthony D Harries Journal: PLoS One Date: 2011-11-02 Impact factor: 3.240
Authors: K Charambira; S Ade; A D Harries; R T Ncube; C Zishiri; C Sandy; H Mutunzi; K Takarinda; P Owiti; P Mafaune; P Chonzi Journal: Public Health Action Date: 2016-06-21
Authors: A M V Kumar; H D Shewade; J P Tripathy; N Guillerm; K Tayler-Smith; S Dar Berger; K Bissell; A J Reid; R Zachariah; A D Harries Journal: Public Health Action Date: 2016-01-04